Journal
Zepbound vs Wegovy: The Head-to-Head Trial, the Price Ladders, and the Honest Tiebreakers
Released: Last reviewed:
The short answer
On the studied endpoint, the head-to-head is settled: SURMOUNT-5 ran Zepbound (tirzepatide) directly against Wegovy (semaglutide 2.4) for 72 weeks and tirzepatide won, 20.2% versus 13.7% average loss — open-label and Lilly-funded, caveats that soften but don't reverse a 6.5-point gap. Everything else on the scorecard is more even than the headline: Wegovy holds the cardiovascular-risk-reduction indication (SELECT's 20% MACE cut — tirzepatide's CV-outcomes trial is still running), Zepbound holds the sleep-apnea indication (SURMOUNT-OSA), Wegovy offers the class's only approved oral option (from $149), and the cash ladders overlap: Zepbound vials $299–$449 with the 45-day rule; Wegovy pens $349 ($199 intro) with the tablet below. The honest routing: efficacy-first buyers lean Zepbound; cardiac-history patients lean Wegovy on indication; diagnosed-OSA patients lean Zepbound on indication; needle-averse and floor-price buyers lean the Wegovy tablet — and insurance formularies overrule everything, because a covered anything beats a cash preference.
The tiebreakers, expanded
When the indications don't decide it: tolerability runs comparable in class terms (GI-dominant, titration-shaped) with individual variation swamping averages — a failed trial of one is a reason to try the other, and switching between molecules is routine prescriber territory. Track record favors semaglutide's longer market history and larger real-world file; ceiling favors tirzepatide's dose-response headroom. Cash economics at maintenance: $449 Zepbound versus $349–$399 Wegovy pens is a $50–$100 monthly brand gap the compounded market inverts ($169–$179 tirzepatide versus $129–$139 semaglutide — tirzepatide costs more compounded, the opposite of the brand relationship, an arbitrage our molecule comparison unpacks). And the coverage reality deserves last word: formulary placement varies plan by plan, both molecules' secondary indications (CV, OSA) open doors the weight indication can't, and the cheapest version of either drug is the covered one — so the comparison every cash page runs should start with the coverage attempt both brands' pages agree on.
Questions people ask
Which works better, Zepbound or Wegovy?
The direct trial (SURMOUNT-5, 72 weeks) favored Zepbound: 20.2% vs 13.7% average loss — open-label and Lilly-funded, but a 6.5-point gap. Individual response varies enough that a poor experience on one is a standard reason to try the other.
Why choose Wegovy if Zepbound lost less weight— I mean won?
Three indication-level reasons: Wegovy's cardiovascular-risk-reduction approval (SELECT) for patients with heart disease, the only approved oral option (tablets from $149), and broader formulary history. Zepbound counters with the sleep-apnea indication and the efficacy edge. Diagnosis and coverage decide more than the headline number.
Which is cheaper, Zepbound or Wegovy?
Cash brand: Wegovy — $149 tablets or $349 pens ($199 intro) versus Zepbound's $299–$449 vials. Compounded, it flips: semaglutide $129–$139 versus tirzepatide $169–$179. Insured: whichever your formulary covers, at copays that beat every cash figure.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.